Burning Rock Dx

11/21/2025

Join our December 9 webinar to discover key aspects of CAP accreditation, insights into the U.S. regulatory landscape including CLIA, and practical strategies for building and maintaining an effective Quality Management System (QMS).

Ensuring quality and compliance is at the core of every successful clinical laboratory. This webinar brings together CAP expert Daniel and Christie, QA leader from Burning Rock, to explore t

11/16/2025

MEDICA 2025 kicks off tomorrow, and we’re excited to be part of it in Düsseldorf!
Our team— Ms. Xinru Mao, Mr. Weisi Liu, and Mr. Daniel G. — is ready to showcase Burning Rock Dx’s commitment to healthcare innovation and strategic global partnerships.

We look forward to reconnecting with our partners and meeting new collaborators as we continue expanding our global portfolio and supporting precision healthcare worldwide.

If you’re interested in exploring collaboration opportunities or learning more about what we do, feel free to reach out at IVDBD@brbiotech.com.
See you at MEDICA 2025!

09/24/2025

👏 New CDx Milestone in Japan!
We’re excited to share that our OncoGuide™ OncoScreen™ Plus CDx System has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for AstraZeneca’s capivasertib (Truqap®) in breast cancer.
This CDx System enables detection of PIK3CA, AKT1, and PTEN alterations in a single test—helping guide treatment decisions and improve patient outcomes.
This achievement marks another step in expanding therapeutic options and advancing precision oncology in Japan. Together with our partners, we continue to shape the future of cancer care. 🌏💡
👉 Read the full announcement: https://www.brbiotech.com/en/details.php?class_id=105107102&id=500

09/22/2025

We’re excited to share that Burning Rock Dx will be joining Biomarker & Precision Medicine 2025 in London, 30 September – 1 October!
📍 Visit us at Booth #44 to explore our comprehensive cancer diagnostic solutions and discuss how we can drive the future of precision oncology together.

05/15/2025

See You at ESHG 2025 – Milan!
We're heading to Milan for the European Human Genetics Conference (May 24–27). Stop by Booth #234 to discover how our innovations in genomic testing are shaping the future of precision diagnostics.

Our team looks forward to connecting with you. Book a meeting with us in advance👉https://lnkd.in/gXmz4RFF

05/13/2025

We're excited to announce that Burning Rock Dx will be exhibiting at !
📍 Booth #26157
Looking forward to connecting with oncology innovators and showcasing our latest cancer diagnostic solutions. See you in Chicago!

04/22/2025

AACR 2025 Conference Poster: 4567

Title: Circulating tumor DNA-based molecular residual disease guides treatment in metastatic colorectal cancer patients with no evidence of disease: an open-label, prospective, phase II study

Conclusions:
❶Patients with negative ctDNA post curative treatment had superior RFS compared with those with positive ctDNA.
❷ctDNA status had the potential to guide ACT in mCRC patients with NED.

Time: April 29, 2025 9:00 AM- 12:00 PM
Session Title: Liquid Biopsy: Circulating Nucleic Acids 2
Location: Poster Section 29
Poster Board Number: 20

Join us to gain an insight into more results about circulating tumor DNA-based molecular residual disease guides treatment in metastatic colorectal cancer patients with no evidence of disease.
For more details, please visit:
https://www.abstractsonline.com/pp8/ #!/20273/presentation/4765

04/16/2025

👋 Meet Our Experts at AACR 2025!

Our team from Burning Rock Dx is excited to be at AACR 2025. Stop by Booth #2157 to chat with our experts.

See you there! 👩‍🔬👨‍🔬

04/16/2025

This webinar explores cutting-edge advancements in ultra-deep circulating tumor DNA (ctDNA) sequencing, integrating artificial intelligence (AI) and precision oncology to address critical ch

04/03/2025

Advancing CNS Metastases Management with CSF ctDNA Profiling
🧠 New Study in Nature Medicine! 🧠
Cerebrospinal Fluid Circulating Tumor DNA Profiling for Risk Stratification and Matched Treatment of Central Nervous System Metastases.
🔬 Key Findings:
✅ CSF ctDNA accurately reflects tumor burden, providing critical prognostic and treatment insights.
✅ A multi-indicator prognostic model enhances risk stratification and supports individualized therapy.
✅ Real-time monitoring of disease progression and resistance mechanisms enables timely treatment adjustments.
✅ Burning Rock’s OncoCompass® Target (168-gene assay) demonstrated exceptional sensitivity in CSF ctDNA detection, while both OncoCompassⓇ Target (168-gene assay) and OncoCompassⓇ Plus(520-gene assay) showed strong prognostic performance.
This research underscores the power of liquid biopsy in neuro-oncology, offering a minimally invasive approach to guide precision medicine.

🌐 Learn more about our publications: https://us.brbiotech.com/publications.php

03/28/2025

Join Our Webinar on ctDNA and Deep Sequencing
📅 April 17, 2025 | ⏰ 8:00 AM (PDT), 11:00 AM (EDT)

We’re hosting a webinar focused on the latest advancements and challenges in ctDNA sequencing and deep sequencing technologies. These innovations are transforming precision oncology by enabling non-invasive cancer diagnosis and monitoring through liquid biopsies. We’ll explore how ultra-deep sequencing and deep learning are enhancing the accuracy of detecting rare mutations, crucial for early detection and treatment monitoring.

Join us to:
1. Understand ctDNA’s role in treatment selection, MRD monitoring, and early cancer detection.
2. Discover how deep learning improves variant detection accuracy.
3. Learn about cutting-edge innovations in ultra-deep sequencing for low-tumor-burden samples.

Don’t miss this opportunity to stay ahead in precision oncology. Register now and gain unlimited on-demand access after the live event: https://www.labroots.com/webinar/precision-oncology-unleashed-challenges-innovations-ctdna-deep-sequencing?campaign=BNR